Skip to content

Safety and Efficacy of Midline and PICC

Safety and Efficacy of Midline and Peripherally Inserted Central Catheter for Intravenous Therapy: a Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03502980
Acronym
MidLine_PICC
Enrollment
293
Registered
2018-04-19
Start date
2018-07-01
Completion date
2022-07-21
Last updated
2022-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Venous Catheter, Vascular Access Devices

Keywords

Peripherally Inserted Central Catheter Line Insertion, Catheterization, Peripheral Venous

Brief summary

The purpose of this study is to assess the non-inferiority for safety and efficacy of using Midline in comparison with PICC for intravenous therapy that do not require a central catheter.

Detailed description

Vascular access devices (VADs), including peripherally inserted central venous catheters (PICCs) remain a cornerstone for the delivery of necessary intravenous therapy. PICCs are being selected for venous access more frequently today than ever before. The advantage of PICC is that it can be used for all intravenous therapy. However, PICC requires the use of fluoroscopy or other type of guidance which add to the cost and time required to insert the catheter. Midline, on the other hand, can be inserted under ultrasound guidance, takes less time to be inserted and cost less than PICC insertion. Despite lower cost and better accessibility of midline in comparison with PICC for non-vesicant intravenous therapy, there is very little evidence in the literature to suggest that one type of venous access is better than the other. The primary objective of this study is to assess the non-inferiority for safety and efficacy of using Midline in comparison with PICC for intravenous therapy that do not require a central catheter. Results of this trial will allow improving a quality of evidence for using midline instead of PICC for specified indications. If Midline are non-inferior for some indications, they would represent a more accessible and less expensive alternative than PICC insertion.

Interventions

DEVICEBard PowerPICC

PICC Insertion

DEVICEBard PowerMidline catheter

Midline Insertion

Sponsors

Centre hospitalier de l'Université de Montréal (CHUM)
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Required intra venous therapy * Expected duration of the venous access: \> 6 days and \< 30days

Exclusion criteria

* Patient has a contraindication to insertion of either a Midline or a PICC relative to the therapy * Patient from other hospitals who come to the CHUM only for the installation of a central line * Decreased cognitive ability to care for device at home * Preexisting bacteremia (ie, existing positive blood cultures that had not been repeated with negative results) * Preexisting venous thrombosis or known hypercoagulable states (such as protein C or S deficiency, antithrombin deficiency, lupus anticoagulant) * Venous access with multiple lumens required * Patients not able to give informed consent * Prior participation to this study * Patient is enrolled in another investigational study * Patients hospitalized in the intensive care unit * Patients who are difficult to puncture and require multiple blood samples

Design outcomes

Primary

MeasureTime frameDescription
% of patients without VAD-related adverse event requiring medical interventionUntil 1 week after VAD retrievalInfections, Thrombophlebitis, Infiltration, Bleeding, Pain, Death
% of patients whose intended or additional I.V treatments could be completed with the VAD without VAD complications, dysfunctions or limitations (ex: need for central access or for additional peripheral or central lumens/catheters)Until 1 week after VAD retrieval

Secondary

MeasureTime frameDescription
Time to first VAD-related adverse eventsUntil 1 week after VAD retrieval
Duration VAD intervention (Midline or PICC)Index procedure
Number of additional interventions to insert the VADIndex procedure
% of patients who experience VAD-related adverse events requiring medical interventionUntil 1 week after VAD retrievalInfections, Thrombophlebitis, Infiltration, Bleeding, Pain, Death
% of patient without failed blood sampling attempts through the VADUntil 1 week after VAD retrieval
% of patients for whom the end of treatment was the reason for VAD retrievalUntil 1 week after VAD retrieval
% of patients who required another VAD to complete the intended or additional iv treatments, either because of VAD complications, dysfunctions or limitationsUntil 1 week after VAD retrieval
Number of VAD-related adverse events requiring medical intervention per 1000 catheter/daysUntil 1 week after VAD retrieval

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026